Inside the fake MMR claims that struck fear into generations of parents

Developing A Vaccine For The 'zombie Drug' Xylazine

Xylazine is an FDA-approved sedative and pain reliever for use in animals, but it has severe adverse effects when used in humans. It is now illicitly being added to opioids, like fentanyl and heroin, as well as cocaine -- leading to a sharp rise in overdose deaths.

Now, Scripps Research chemical biologists have developed a vaccine to block the effects of xylazine's toxicity. The vaccine works by training the immune system to attack the drug, which is described in a new paper published in Chemical Communications on April 1, 2024.

"We demonstrated that a vaccine can reverse the symptoms of a xylazine overdose in rodents," says study senior author Kim D. Janda, PhD, the Ely R. Callaway, Jr. Professor of Chemistry at Scripps Research. "There is currently no remedy for xylazine poisoning other than supportive care, thus, we believe our research efforts and the data we have provided will pave the way for an effective treatment in humans."

The rapid increase in lethal drug overdoses attributed to xylazine combined with fentanyl prompted the White House Office of National Drug Control Policy to declare this combination an emerging threat to the United States. Xylazine intoxication presents similarly to opioid overdose, causing respiratory and central nervous system depression, and it can heighten the effects of opioids. However, naloxone -- typically administered to reverse the effects of opioids -- does not tackle the impact of xylazine, highlighting the need for effective measures to treat acute toxicity caused by xylazine.

Researchers suspect xylazine works by reducing blood flow to the brain, among other areas of the body. The drug also causes non-healing skin lesions and wounds, often located on the forearms and lower legs, that can require amputation in some cases -- giving it the nickname "zombie drug."

Although no treatment currently exists, targeted vaccines may offer a solution. Vaccines nudge the immune system to create antibodies to fend off invaders. Antibodies can target viruses, bacteria and toxins. However, sometimes molecules are too small to initiate an immune response, as is the case with xylazine. So, to circumvent this problem, the researchers created a vaccine using a design principle that Janda pioneered, which relies on pairing the drug molecule (called a hapten) with a larger carrier molecule (a protein) and an adjuvant.

In this study, the scientists combined a xylazine hapten with multiple different protein types, to see which combination would create a robust immune response against xylazine. The team tested three vaccine formulations (termed TT, KLH and CRM197, based on the protein involved) to see which vaccine cocktail could help rodents after being challenged with xylazine. One of the three vaccines (TT) significantly increased movement in mice given xylazine after 10 minutes, while two of the three vaccines (TT and KLH) led to an improvement in breathing.

The scientists also examined how these vaccines would limit xylazine blood brain barrier, (BBB) permeation, a filtering mechanism that scrutinizes drug penetration. When xylazine was injected, it immediately crossed into the brain to bind with receptors. Antibodies typically cannot navigate the BBB; however, two of the three vaccines (TT and KLH) showed a strong ability to stop xylazine from reaching its receptors in the brain, limiting its detrimental effects.

A provisional patent has been filed on the research. In the future, his team will build off this work to create a bifunctional antibody that will reverse both fentanyl and xylazine's toxicity simultaneously, something that naloxone cannot do.

"A monoclonal antibody treatment could be given in tandem with the vaccine to provide both immediate and long-term protection from both opioid substance use disorders as well as opioid-xylazine overdoses," says Janda. "This strategy could make a significant impact on the opioid epidemic."

"Evaluation of a Hapten Conjugate Vaccine Against the 'Zombie Drug' Xylazine" was co-authored by Mingliang Lin, Lisa M. Eubanks, Bin Zhou, and Kim D. Janda, all of Scripps Research.

Funding for the study was provided by the Shadek family and Pearson Foundation.

TicketMaster Parent Live Nation Facing DOJ Antitrust Lawsuit As Soon As May: Report

The Justice Department is preparing to file an antitrust lawsuit against Live Nation as soon as next month, the Wall Street Journal reported on Monday, citing people familiar with the matter.

Live Nation's subsidiary Ticketmaster, which for decades has been condemned for hardball tactics and high prices, was also widely criticized in 2022 after botched ticket sales for Taylor Swift's "Eras" tour, feeding demands that the two companies be investigated for harming consumers.

The lawsuit would allege that Live Nation had leveraged its dominance in a way that undermined competition for ticketing live events, the WSJ report said.

Live Nation's subsidiary Ticketmaster was also widely criticized in 2022 after botched ticket sales for Taylor Swift's "Eras" tour. REUTERS

The DOJ and Live Nation did not respond to Reuters' request for comment.

Shares of the Ticketmaster-parent dropped about 6% in extended trading.

The lawsuit would allege that Ticketmaster parent Live Nation had leveraged its dominance in a way that undermined competition for ticketing live events, according to the report. SOPA Images/LightRocket via Getty Images

Last year, Live Nation was issued a subpoena by a US Senate panel for documents pertaining to ticket pricing, fees and secondary sales.

Vaccines News

Mar. 20, 2024 — A powerful new tool in artificial intelligence is able to predict whether someone is willing to be vaccinated against ...

Mar. 14, 2024 — Scientists recently published the results of a competition that put researchers to the test. For the competition, part of the NIH-funded Computational Models of Immunity network, teams of researchers ...

Mar. 7, 2024 — The COVID vaccine is safe to administer during pregnancy, researchers report in an important finding on the safety of the vaccine in infants -- despite widespread fear and ...

Mar. 4, 2024 — A vaccine against Zika virus is safe and effective when administered both before and during pregnancy, according to new ...

Mar. 1, 2024 — Researchers have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored 'dark side' of the neuraminidase (NA) protein ...

Mar. 1, 2024 — The most recent COVID-19 booster shot reduces adults' risk of moderate or severe COVID by more than half, according to a new nationwide data study from September 2023 through January 2024, a ...

Feb. 29, 2024 — U.S. Flu vaccines are likely to move from quadrivalent to trivalent due to a change in circulating influenza viruses, according to a new ...

Feb. 28, 2024 — The eyes have been called the window to the brain. It turns out they also serve as an immunological barrier that protects the organ from pathogens and even tumors, researchers have found. In a new ...

Feb. 26, 2024 — A long-term analysis reveals that antibody responses induced by COVID-19 vaccines are long-lasting. The study results challenge the idea that mRNA-based vaccine immunity wanes ...

Feb. 26, 2024 — A research team has developed a recombinant protein flu vaccine candidate. It utilizes a nanoliposome vaccine platform that underwent phase 2 and phase 3 clinical trials in South Korea and the ...

Feb. 22, 2024 — First large-scale analysis of optimal timing for flu shots finds October is the best month for children to get vaccinated against influenza. Study of 800,000 pediatrician visits leverages links ...

Feb. 21, 2024 — Could the TB vaccine be a new immunotherapy for liver cancer? A study found that the century-old vaccine reduced tumors and extended survival for mice with liver ...

Feb. 20, 2024 — A study has shown that shortly after an increase in antimicrobial use -- specifically the antibiotic ciprofloxacin -- rates of antimicrobial-resistant Salmonella typhi ...

Feb. 20, 2024 — Researchers found that PD-1-enhanced DNA vaccination can induce sustained virus-specific CD8+ T cell immunity in an AIDS monkey model. The vaccinated monkeys remained free of AIDS for six years and ...

Feb. 19, 2024 — The prospect of the worrisome triple threat of COVID, RSV and flu was assuaged last year by the effectiveness of flu vaccines. Two recent studies from the Centers for Disease Control and ...

Feb. 14, 2024 — Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with strong protection against symptomatic COVID-19 infection for at least six months after ...

Feb. 6, 2024 — New research reveals as much as a four-fold increase in immune response when people alternate from one arm to the other when given a multi-dose ...

Feb. 6, 2024 — Scientists have uncovered important clues to how human T cells combat Mycobacterium tuberculosis, the bacterium that causes ...

Feb. 2, 2024 — Seeing a glycoprotein on the envelope of the HIV virus snap open and shut in mere millionths of a second is giving investigators a new handle on the surface of the virus that could lead to broadly ...

Jan. 30, 2024 — Using a DNA-based delivery particle, researchers created a vaccine that can induce a strong antibody response against ...

---